Monogram Announces Commercial Availability of the HERmark(TM) Breast Ca...(e report indicates HERmark status of po...),Health

Date:7/8/2008

e report indicates HERmark status of "positive", "negative" and "equivocal". The boundaries for the equivocal zone represent an upper level above which 95% are positive and a lower level below which 95% are negative patients. Additional information on the HERmark Breast Cancer Assay can be found at http://www.hermarkassay.com.

Clinical data: Preliminary data from three cohorts of Herceptin-treated patients with metastatic breast cancer who were identified as "HER2 positive" by conventional assays suggest that HERmark can identify patients who are likely to respond to Herceptin with greater precision than currently available tests. Additional studies of HERmark for breast cancer in both the metastatic and adjuvant settings are in progress.

About VeraTag

VeraTag is a proximity-based assay technology platform that accurately quantifies proteins and functional protein complexes. This platform provides a researcher or clinician a more thorough understanding of protein-protein interactions or signaling pathway activity allowing for disease characterization at the molecular level. Assays based on the VeraTag technology platform are designed to run on standard formalin-fixed paraffin embedded (FFPE) patient samples.

About Monogram

Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved anti-viral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.
'/>"/>

SOURCE Monogram Biosciences, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. Monogram Biosciences Collaborates with Gilead Sciences for Elvitegravir Phase III Studies
2. Monogram Biosciences Announces Immediate Availability of Enhanced Sensitivity Trofile(TM) HIV Tropism Assay
3. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
4. Monogram Announces First Medicare Payment for Trofile(TM)
5. The Center for Professional Innovation and Education (CfPIE) Announces the First True Certification Program for Document Management Professionals in the Life Sciences
6. The Center for Professional Innovation and Education (CfPIE) Announces a New Global Regulatory Certification Track
7. GRAS Proudly Announces Photometrica Version 2.0. Hailed as a Brilliant Solution for More Productive Astronomical Research by Those Engaged in Photometry Using the Global-Rent-a-scope Telescope Systems
8. NHP Announces Second Quarter Earnings Release Date and Conference Call/Webcast
9. Ventas Announces 2008 Second Quarter Earnings Release Date and Conference Call
10. QuikByte Software, Inc. Announces Changes to Board of Directors and Executive Ranks
11. March of Dimes Announces Nursing Scholarship Recipients